Patient Participation

Webinar Date/Time: Thursday, March 12th, 2026 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET

Amid mounting political and legal pressure, corporate DEI efforts, particularly in life sciences, are largely holding steady, with leadership, boards, and shareholders continuing to frame inclusion as a strategic driver of innovation, performance, and representative clinical research.

As Parkinson’s disease cases surge worldwide, growing evidence gaps around women’s biology, care access, and outcomes are driving new data-driven and digital strategies to advance sex-specific research and precision medicine.

As AI-driven search becomes the primary way patients discover research opportunities, the quality and structure of clinical trial registry data will determine whether transparency translates into real, equitable access.

Explore how sponsors can recalibrate efficiency efforts to avoid overconcentrating trials at familiar sites and instead expand access through community partnerships, point-of-care research, and intentional outreach models.

Understand which barriers to cancer trial participation remain most difficult to overcome, including geography and trial centralization, and how decentralized approaches and care delivery closer to home may help close access gaps.

Explore early data from the ACTS program that reveal the volume and types of patient-reported barriers to cancer care and clinical trial participation, highlighting the critical role of support services in sustaining enrollment.

Examine how the American Cancer Society’s national ACTS expansion is designed to simplify trial discovery, reduce logistical barriers, and help patients, caregivers, and providers navigate cancer clinical trials through a centralized support model.

New research finds that while eSource adoption is advancing through EHR-to-EDC workflows, scaling its impact will depend on integrating unstructured clinical data using AI, shared standards, and collaborative validation models across sites, sponsors, and vendors.

Webinar Date/Time: Thu, Jan 22, 2026 11:00 AM EST

Discover how remote assessments, wearables, and digital technologies can decentralize data collection, reduce patient burden, and enable trials to reach more diverse and representative populations.

Learn how sponsors and CROs are adapting to evolving ICH GCP requirements while maintaining innovation in high-touch areas, ensuring patient protection, and preserving data integrity across global clinical trials.

Examine the rise of personalized and biomarker-driven therapies, the logistical challenges of rare patient populations, and how historical controls and real-world evidence are supporting strategy-driven trial designs.

Emerging applications of AI/ML, automation, and digitization are helping sponsors cut clinical trial start-up times to as little as four weeks, reduce data errors, and enhance patient engagement—demonstrating how tech-enabled processes are reshaping trial efficiency and experience across the study lifecycle.

In this episode of the ACT Podcast, Jeneen Donadeo, executive director of portfolio management at TransCelerate, and Laura Galuchie, senior director and TransCelerate program lead at Merck, discuss the findings from a recent TransCelerate and Tufts CSDD study revealing that nearly one-third of data collected in Phase III trials is non-essential. They explore why trial complexity continues to grow despite industry efforts toward efficiency and share strategies for reducing data burden while maintaining compliance.

Highlighting how technology and mindset shifts can help expand breast cancer research leadership beyond high-income countries and build more inclusive global trial networks.

Webinar Date/Time: Mon, Nov 17, 2025 11:00 AM EST

As decentralized and hybrid trial models expand, eConsent is emerging as a critical tool for improving participant understanding, reducing site burden, and strengthening data integrity through digital automation, accessibility, and regulatory compliance.

See how early patient inclusion, integrated regulatory planning, and seamless CRO partnerships can help biotechs accelerate progression from Phase I to Phase II.

Advancing toward more meaningful use of PRO data by making it systematic, transparent, and built into trial design.

The quest to turn patient retention from a chronic challenge into a competitive strength—and one that benefits all stakeholders.

Why discussions with patients should go deeper than data-centered dialogues—and emphasize trust, personal connections, and community engagement to foster informed choices in public health.

Webinar Date/Time: Wed, Oct 22, 2025 11:30 AM EDT